SCHEMBL5618954

SCHEMBL5618954

CNc1nccn2c(-c3ccc4[nH]ccc4c3)cnc12

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 4/20 0.51
▸ TTK P33981 2/20 0.45
▸ FYN P06241 2/20 0.45
▸ EED O75530 1/20 0.45
▸ DYRK3 O43781 4/20 0.44
▸ CCNT1 O60563 4/20 0.44
▸ CDK9 P50750 4/20 0.44
▸ CDK5 Q00535 4/20 0.44
▸ DYRK1A Q13627 4/20 0.44
▸ CDK5R1 Q15078 4/20 0.44
▸ DYRK2 Q92630 4/20 0.44
▸ DYRK1B Q9Y463 4/20 0.44
▸ CCNA2 P20248 3/20 0.44
▸ CDK2 P24941 3/20 0.44
▸ ERN1 O75460 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ SYK P43405 1/20 0.41
▸ GRIA1 P42261 1/20 0.41
▸ MAPKAPK5 Q8IW41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471563 0.82 ERN1 (0.46) TTKEEDDYRK3CCNT1CDK9
SCHEMBL5401140 0.81 FLT3 (0.55) FLT3TTK
SCHEMBL5618947 0.79 DYRK3 (0.44) TTKFYNEEDDYRK3CCNT1
SCHEMBL11939102 0.79 TTK (0.45) TTKFYNEEDERN1SYK
SCHEMBL5618420 0.78 FLT3 (0.46) FLT3TTKGRIA1
SCHEMBL5617891 0.78 FLT3 (0.52) FLT3TTKGRIA1
SCHEMBL5406217 0.77 FLT3 (0.53) FLT3TTKGRIA1MAPKAPK5
SCHEMBL5413864 0.77 KDM4E (0.55) FLT3TTK
SCHEMBL3470478 0.76 MAPKAPK5 (0.43) FLT3TTKFYNEEDADORA3
SCHEMBL8241606 0.76 AURKA (0.58) FLT3DYRK1ASYKMAPKAPK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US claimed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 FLT3 216/4885TTK 69/4885FYN 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback